Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03735498 | Psychological Intervention for Caregivers of Patients With Malignant Gliomas | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03922984 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | completed | N/A | 43 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05427214 | Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy(Dragon) | completed | N/A | 52 | Washington University School of MedicineOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04304300 | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes(RIGEL) | completed | — | 80 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03926507 | F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery | completed | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01811992 | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | completed | Phase 1 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03278249 | Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | completed | N/A | 12 | University of CincinnatiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600399 | Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma(PSMA，ASL，PET) | completed | — | 26 | Lanzhou University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03995706 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | completed | Early Phase 1 | 26 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT01204684 | Dendritic Cell Vaccine for Patients With Brain Tumors | completed | Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04013672 | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | completed | Phase 2 | 41 | David PeereboomOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03284268 | Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma(RTB) | completed | N/A | 13 | Fundació Sant Joan de DéuOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT01923922 | CT Perfusion in the Prognostication of Cerebral High Grade Glioma | completed | N/A | 48 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06562621 | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 38 | Beijing Neurosurgical InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | completed | Phase 2 | 25 | NovoCure GmbHINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05977738 | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin(ReDiReCCT-Pita) | completed | Early Phase 1 | 12 | C.DirvenOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT00601003 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | completed | Phase 2 | 112 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01802567 | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | completed | N/A | 52 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04497142 | Effect of Perampanel on Peritumoral Hyperexcitability in HGG | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06538428 | Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients | completed | — | 78 | Ain Shams UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06038604 | Glioblastoma Psychosocial Support Program | completed | N/A | 11 | Duke UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06454266 | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | completed | Phase 2 | 22 | Ningbo No. 1 HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03493932 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | completed | Phase 1 | 21 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02441322 | Evaluating Therapeutic Response to Novo-TTF | completed | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT01817751 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 47 | Virginia Commonwealth UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06490497 | Expectations and Needs of a Glioblastoma Caregiver(GLOIOS) | completed | — | 9 | Hopital Nord Franche-ComteOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06346821 | Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data | completed | — | 181 | Sichuan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT04937413 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | completed | Early Phase 1 | 32 | Duke UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02014844 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | completed | Phase 2 | 28 | ImmunityBio, Inc.INDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05402241 | IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study(IRD-GBM) | completed | — | 52 | University of ManitobaOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02067156 | Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 26 | GenSpera, Inc.INDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04296617 | Brain Imaging Changes Following Proton Therapy for Pediatric Primary Central Nervous System and Base of Skull Tumors | completed | — | 36 | Mayo ClinicOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03139916 | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04143425 | Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | completed | — | 15 | Ho Sung KimOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT00653068 | Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System | completed | Phase 3 | 70 | Children's Oncology GroupNETWORK | 3 | Apr 23, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 13, 2024source: clinicaltrials